H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Cipralex/Lexapro for depression. It also provides Northera for symptomatic neurogenic orthostatic hypotension; Onfi for epilepsy; Sabril for refractory complex partial seizures and infantile spasms; Ebixa for dementia, Azilect for Parkinson's disease; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol for psychosis. In addition, the company develops Eptinezumab for migraine prevention; Eptinezumab, which is in phase 3 clinical trial for cluster headache; Lu AG09222, which is in phase 2 clinical trial for migraine prevention; Lu AG13909 that is in phase 1 clinical trial for neurohormonal dysfunctions; Brexpiprazole for post-traumatic stress disorder; Lu AF28996, which is in phase 1 clinical trial for Parkinson's disease; MAGLi program that is in phase 1 clinical trial for neurology; Bexicaserin, which is in phase 3 clinical trial for developmental and epileptic encephalopathies; Amlenetug that is in phase 3 clinical trial for synucleinopathies; and Lu AG22515, which is in clinical phase 1 clinical trial for neurology. Lundbeck A/S has a strategic research collaboration with Contera Pharma to develop oligonucleotide-based medicines for patients living with serious neurological conditions. The company was founded in 1915 and is headquartered in Valby, Denmark.
Frequently asked questions
What sector does H. Lundbeck A/S (HLBBF) operate in?
H. Lundbeck A/S belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is H. Lundbeck A/S (HLBBF) current stock price?
As of the latest data, H. Lundbeck A/S stock price is $7.10, with a previous close of $7.10.
What is H. Lundbeck A/S (HLBBF) current market capitalization?
H. Lundbeck A/S market cap is approximately 5.63 billion.
What is H. Lundbeck A/S (HLBBF) Earnings Per Share (EPS)?
The trailing EPS is $0.61.
What is H. Lundbeck A/S (HLBBF) Price-to-Earnings (P/E) ratio?
H. Lundbeck A/S current P/E ratio is 11.64.
What is H. Lundbeck A/S (HLBBF) EBITDA?
H. Lundbeck A/S EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 308.63 million.
Does H. Lundbeck A/S (HLBBF) pay dividends?
Yes. H. Lundbeck A/S pays annual dividends with an annualized yield of 2.56% and an estimated annual payout of $0.18 per share.
When is the next ex-dividend date for H. Lundbeck A/S (HLBBF)?
The next ex-dividend date is scheduled for March 20, 2027.
How did H. Lundbeck A/S (HLBBF) perform in its most recent earnings report?
In the last report (June 30, 2026), H. Lundbeck A/S posted an EPS surprise of -87.92% and a revenue surprise of -84.08%.
What is H. Lundbeck A/S (HLBBF) beta (volatility) score?
H. Lundbeck A/S has a beta of 0.241, indicating lower volatility than the overall market.
